Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$26.96 USD
+0.82 (3.14%)
Updated Sep 25, 2025 04:00 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VERA 26.96 +0.82(3.14%)
Will VERA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VERA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERA
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
VERA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VERA
Reversal New Highs Setup appears for VERA after 3.14% move
VERA forms NR7 on September 25
VERA forms Stochastic Sell Signal on September 23
VERA forms Slingshot Bullish on September 23
VERA forms Upper Bollinger Band Walk on September 19